Eye scans could reveal hidden clues about MS drug effectiveness

NCT ID NCT06864936

Recruiting now Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study will test whether a special eye scan (OCT) can detect changes in the retina that show how well the MS drug ublituximab is working. Researchers will compare 15 people starting ublituximab with 15 people on other MS treatments. The goal is to find a new, non-invasive way to monitor treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ublituximab
What this could lead to: If successful, this could lead to a new way to monitor MS treatment response using simple eye scans, potentially improving care.
What could go wrong: This is a small, early-stage study focused on biomarkers, not on proving the drug works. The new imaging method may not prove useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING

Contacts and locations

Locations

University of Maryland, Baltimore
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.